EP0550638A4 - Medium for culture of mammalian cells - Google Patents

Medium for culture of mammalian cells

Info

Publication number
EP0550638A4
EP0550638A4 EP19910918096 EP91918096A EP0550638A4 EP 0550638 A4 EP0550638 A4 EP 0550638A4 EP 19910918096 EP19910918096 EP 19910918096 EP 91918096 A EP91918096 A EP 91918096A EP 0550638 A4 EP0550638 A4 EP 0550638A4
Authority
EP
European Patent Office
Prior art keywords
per liter
medium
milligrams per
serum
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19910918096
Other languages
English (en)
Other versions
EP0550638A1 (en
Inventor
Luciano Ramos
Amy Anne Murnane
Melvin Susumu Oka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0550638A1 publication Critical patent/EP0550638A1/en
Publication of EP0550638A4 publication Critical patent/EP0550638A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/74—Undefined extracts from fungi, e.g. yeasts

Definitions

  • the present invention relates to the field of cell culture media. More particularly the invention relates to the field of mammalian cell culture media. Background of the Invention
  • serum-free media Beyond a basal nutrient mixture of salts, sugars, amino acids, and vitamins, cells .in vitro have also been found to require for proliferation a supplement of poorly defined biological fluids or extracts. Because of availability and ease of storage, the most commonly used supplement is serum.
  • the use of serum in cell culture media has several disadvantages. Serum is comparatively expensive. Since serum is not a defined component, different lots of serum may vary in the concentration of compounds present and thus result in unpredictable culture growth. Serum may also be contaminated with viruses or mycoplasms. The protein in serum may complicate the purification of cell products from the culture medium. In efforts to overcome the disadvantages of serum containing medium, researchers have attempted to provide serum-free media by substituting defined or better characterized components for serum.
  • U.S. Patent 4,786,599 issued November 22, 1988 to Chessebeuf and Padieu discloses a serum-free animal tissue culture medium containing a mixture of six fatty acids and albumin or dextran.
  • the medium is particularly adapted for the primary culture of rat liver epithelial cells and possibly in the presence of hormones and/or growth factors, for obtaining cell lines, in particular myeloma and hybridoma cell lines.
  • Cytobiologica 2_6 123-132 report a serum-free medium for the culture of chick embryo cells containing dextran.
  • Pietrzkowski and Korohoda (1988) Folia Histochemica et Cytobiologica _ ⁇ 143-154 report a serum-free medium containing dextran for the culture of chick embryo fibroblasts. In these two publications, the dextran was added to the medium to enhance cell attachment and spreading.
  • Ohmori (1988) Journal of Immunological Methods 112: 227-233 reports a serum-free medium which is able to support primary antibody responses by cultured murine lymphocytes. This medium is based on a basal medium supplemented with ⁇ - cyclodextrin, insulin, transferrin, albumin, low density lipoprotein, putrescine and alanine.
  • R-innmai- ⁇ of the Invention The present invention provides media for the culture of mammalian cells. The invention is more particularly pointed out in the appended claims and is described in its preferred embodiments in the following description. Detailed Description of the Invention The media of the invention are useful for the culture of mammalian cells.
  • the media of the invention have been found to be useful in the culture of Chinese hamster ovary (CHO) cells, and HAK cells, a baby hamster kidney cell line.
  • the media of the invention have been found not suitable for the culture of myeloma cell lines.
  • Cells may be grown in batch and continuous culture with the serum-frae media of the invention.
  • CHO cells grown in the media of the invention reach higher cell density and show increased recombinant product secretion when compared to CHO cells grown in a serum-containing medium.
  • the cell culture media of the invention are prepared by adding components to a basal medium designed for mammalian cell culture.
  • the media are prepared in accordance with standard procedures for preparing cell culture media.
  • Suitable basal media include standard mammalian cell culture media such as Ham's medium, Waymouth MB 752/1 medium. Eagle's medium, Williams E medium, 199 medium and derived edia of the types MEM and MEM ⁇ and any combinations of these media.
  • Other standard media used for the culture of mammalian cells are also suitable for use in the invention.
  • a preferred basal medium is the basal medium of Example 1.
  • the preferred basal medium supports cell growth and significantly reduces the size of cell clumps in the media during cell culture.
  • a yeast hydrolysate such as Yeastolate is added to the basal medium in the amount of from about 0.1 to about 10.0 grams per liter, preferably in an amount of about 5 grams per liter.
  • Albumin or dextran is added to the basal medium, in an amount of from about 0.1 to about 5.0 grams per liter.
  • bovine serum albumin or dextran having a molecular weight of about 500,000 is added to the basal medium.
  • Bovine serum albumin is preferably added in the amount of from about 0.1 to about 0.5 grams per liter.
  • Dextran having a molecular weight of about 500,000 such as Dextran T500 is preferably added to the basal medium in the amount from about 0.1 to about 1.0 grams per liter.
  • Insulin is added to the basal medium in the amount of from about 2.0 to about 20 milligrams per milliliter, preferably in the amount of about 10 milligrams per liter.
  • Transferrin or transferrin substitute is added to the basal medium in the amount of from about 0 to about 100.0 micrograms per milliliter.
  • Transferrin may be substituted in the medium with ferric fructose (from about 1.0 to about 10.0 milligrams per liter) , ferric citrate (from about 1.0 to about 100.0 milligrams per liter), or ferrous sulfate (from about 5.0 micromoles to about 200.0 micromoles per liter).
  • ferric fructose from about 1.0 to about 10.0 milligrams per liter
  • ferric citrate from about 1.0 to about 100.0 milligrams per liter
  • ferrous sulfate from about 5.0 micromoles to about 200.0 micromoles per liter.
  • a mixture of the fatty acids oleic, linoleic and linolenic are added to the basal medium in the ratio of oleic 0.6: linoleic 1: linole
  • oleic acid is preferably added to the basal medium in the amount of from about 0.012 to about 0.12 milligrams per liter; linoleic acid is preferably added to the basal medium in the amount of from about 0.2 to about 5.0 milligrams per liter; linolenic acid is added to the medium in the amount of from about 0.028 to about 0.7 milligrams per liter. Cholesterol is added to the basal medium in the amount of from about 0 to about 10.0 milligrams per liter.
  • CaCl 2 (anhydrous) is added to the basal medium in the amount of from about 0 to about 200 milligrams per liter, preferably in the amount of about 66.67 milligrams per liter.
  • Magnesium sulfate (MgSO (anhydrous) is added to the basal medium in the amount of from about 0 to about 100.0 milligrams per liter, preferably in the amount of about 24 milligrams per liter.
  • the pH of the medium is preferably from about 6.8 to about 7.4.
  • the osmolarity of the medium is preferably from about 280 to 360 milliosmoles.
  • the basal medium may be stored as a powder at 4 * C for one year.
  • the complete medium (basal medium with added supplements) in a liquid form may be stored at 4 ⁇ C for six months.
  • the components in the basal media are mixed and ball-mill ground to formulate a homogeneous powder.
  • the powdered media is then dispensed into 100L packets and stored at 4'C.
  • L-Alanine 41 300000 L-Arginine HCl 112.546700 L-Arginine FB 16.666000 L-Asparagine H20 28.336700 L-Aspartic Acid 24.433300 L-Cystine 2HC1 19.116600 L-Cysteine HC1.H20 45.040000 L-Cysteine FB 13.333300 L-Glutamic Acid 46.566700 L-Glutamine 292.000000 Glycine 35.833300
  • Vitamin B12 0.973300
  • Methyl Linoleate 0.010000 Vitamin A Acetate 0.033000
  • Medium MRl-3 contains the basal medium of Example 1 supplemented with 5,000 mg/1 TC Yeastolate (Difco, Detroit, Michigan) , 500 mg/1 bovine serum albumin (BSA) (Armour, Kankakee, Illindis) 10 mg/1 bovine insulin (Waitaki, Toronto, Canada), 10 mg/1 bovine transferrin (Sigma Chemical Co., St.
  • the medium is prepared as follows:
  • Medium MR1-6 is contains the basal medium of Example 1 supplemented with 5,000 mg/1 TC Yeastolate (Difco, Detroit, Michigan) , 500 mg/1 bovine serum albumin (Armour, Kankakee, Illinois) , 10 mg/1 bovine insulin (Waitaki, Toronto, Canada) , 10 mg/1 bovine transferrin (Sigma Chemical Co., St. Louis, Missouri), 0.12 mg/1 oleic acid (Ameresco, Cleveland, Ohio), 0.20 mg/1 linoleic acid (Ameresco), 0.028 mg/1 linolenic acid (Ameresco) , and 2 mg/1 cholesterol (Ameresco) .
  • the medium is prepared in the same way as medium MRl-3 in Example 2 except that steps 3 and 4 are omitted. In this medium no additional MgS0 4 or CaCl 2 is added.
  • Example 4 Preparation of Medium MRl-7.
  • Medium MRl-7 contains the basal medium of Example 1 supplemented with 5,000 mg/1 TC Yeastolate (Difco, Detroit, Michigan), 1,000 mg/1 Dextran T-500 (Pharmacia, Piscataway, New Jersey), 10 mg/1 bovine insulin (Waitaki, Toronto, Canada) , 10 mg/1 bovine transferrin (Sigma Chemical Co, St.
  • Mediun MRl-7 is prepared in the same way as medium MRl-3 in Example 2 except that steps 3 and 4 are omitted and Dextran T-500 replaces bovine serum albumin in step 6. At step 6, 100 grams of Dextran T-500 are added and mixed until dissolved. • By.» ⁇ t ⁇ * ⁇ «» 5 Cell Culture
  • CHO cells transformed to produce soluble T4 lymphocytic cell receptor (cell line 37-80N) were cultured in four different media: serum containing medium Alpha (-) MEM/5% Fetal bovine serum (FBS) , and the media described in Examples 2, 3, and 4. 5 x 10 5 cells per milliliter were cultured for 7 days after seeding in 250 ml SP flasks with 150 ml of medium. Total cell number was determined by Coulter counter, and viability was determined by trypan blue dye exclusion using a hemocytometer. Concentration of ST4 was determined by an ELISA-based assay. At day two after seeding, the serum-free media showed greater number of cells than the serum containing medium.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP19910918096 1990-09-25 1991-09-20 Medium for culture of mammalian cells Ceased EP0550638A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58801790A 1990-09-25 1990-09-25
US588017 1990-09-25

Publications (2)

Publication Number Publication Date
EP0550638A1 EP0550638A1 (en) 1993-07-14
EP0550638A4 true EP0550638A4 (en) 1993-12-08

Family

ID=24352124

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910918096 Ceased EP0550638A4 (en) 1990-09-25 1991-09-20 Medium for culture of mammalian cells

Country Status (11)

Country Link
EP (1) EP0550638A4 (enrdf_load_stackoverflow)
JP (1) JPH06500918A (enrdf_load_stackoverflow)
AU (1) AU662491B2 (enrdf_load_stackoverflow)
CA (1) CA2091443A1 (enrdf_load_stackoverflow)
IE (1) IE913345A1 (enrdf_load_stackoverflow)
MX (1) MX9101254A (enrdf_load_stackoverflow)
NZ (1) NZ239900A (enrdf_load_stackoverflow)
PT (1) PT99048B (enrdf_load_stackoverflow)
TW (1) TW240247B (enrdf_load_stackoverflow)
WO (1) WO1992005246A1 (enrdf_load_stackoverflow)
ZA (1) ZA917561B (enrdf_load_stackoverflow)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE501217C2 (sv) * 1990-12-06 1994-12-12 Skandigen Ab Cellproliferationsmatris och användning därav
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
JP2000507812A (ja) 1996-03-12 2000-06-27 ライフ テクノロジーズ，インコーポレイテッド 造血細胞培養栄養補充成分
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
WO1998015614A1 (en) * 1996-10-10 1998-04-16 Life Technologies, Inc. Animal cell culture media comprising plant-derived nutrients
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
MXPA03002513A (es) 2000-11-23 2004-09-10 Bavarian Nordic As Variante modificada de virus vaccinia ankara.
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
EA009008B1 (ru) * 2002-09-05 2007-10-26 Бавариан Нордик А/С Способ амплификации вируса оспы
GB2404665B (en) 2003-08-08 2005-07-06 Cambridge Antibody Tech Cell culture
EP1651754B1 (en) * 2003-08-08 2007-04-11 Cambridge Antibody Technology Limited Myeloma cell culture in transferrin-free low iron medium
WO2020127613A1 (en) * 2018-12-21 2020-06-25 Genfit In vitro model of liver steatosis and fibrosing non-alcoholic steatohepatitis
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325190A2 (de) * 1988-01-18 1989-07-26 Roche Diagnostics GmbH Pentosansulfat-Medium

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2543158B1 (fr) * 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
AU4254489A (en) * 1989-10-03 1991-04-11 Ajinomoto Co., Inc. Method of induction and activation of cytotoxic t cells
EP0550678B1 (en) * 1990-09-25 1997-12-29 Smithkline Beecham Corporation Media for culture of drosophila cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325190A2 (de) * 1988-01-18 1989-07-26 Roche Diagnostics GmbH Pentosansulfat-Medium

Also Published As

Publication number Publication date
IE913345A1 (en) 1992-02-25
TW240247B (enrdf_load_stackoverflow) 1995-02-11
CA2091443A1 (en) 1992-03-26
WO1992005246A1 (en) 1992-04-02
PT99048A (pt) 1992-08-31
EP0550638A1 (en) 1993-07-14
ZA917561B (en) 1992-09-30
AU662491B2 (en) 1995-09-07
JPH06500918A (ja) 1994-01-27
PT99048B (pt) 1999-02-26
MX9101254A (es) 1992-05-04
NZ239900A (en) 1993-09-27
AU8734891A (en) 1992-04-15

Similar Documents

Publication Publication Date Title
AU662491B2 (en) Medium for culture of mammalian cells
EP0283942B1 (en) Basal nutrient medium for cell culture
Gregory Hamilton et al. Clonal growth of Chinese hamster cell lines in protein-free media
USRE30985E (en) Serum-free cell culture media
CN102827804B (zh) 适用于Vero细胞微载体悬浮放大培养的培养基及方法
JP5431361B2 (ja) 改善された培養培地添加物及びそれを用いる方法
US7462487B2 (en) Cell culture media
CN106190950A (zh) 一种cho细胞无血清无蛋白培养基及其制备方法
CN105567628B (zh) 一种全悬浮培养mdck细胞的低血清培养基
EP0659880B1 (en) Medium for culturing animal cells or antibody-producing cells
CN113913368A (zh) 适合cho细胞大规模悬浮扩增培养的无血清培养基及其制备和应用
CN111518768B (zh) 一种适用于lmh细胞贴壁培养的低血清培养基及其制备方法
CN102021139A (zh) 一种中国仓鼠卵巢细胞培养基及其制备方法和应用
JPS5974982A (ja) 細胞をインビトロで生長させるための細胞生長培地補足剤およびそのための方法
CN116790477A (zh) 一种支持cho细胞高密度培养的无血清培养基及其制备方法与应用
CN110117573A (zh) 一种无血清细胞培养基及其应用
CN111500532B (zh) 心肌细胞诱导和生长培养基
JPH03180176A (ja) 細胞培養のための基礎栄養培地
Agy et al. Protein-free medium for C-1300 mouse neuroblastoma cells
US5641678A (en) Serum-free culture medium for drosphila insect cells
IE913346A1 (en) Media for culture of insect cells
Lee et al. The effects of various hormones and growth factors on the growth of human insulin-producing cell line in serum-free medium
CN106978390B (zh) 适用于贴壁型cho细胞的无血清培养基及培养方法
Donta Growth of functional glial cells in a serumless medium
Mizrahi et al. Department of Biotechnology, Israel Institute for Biological Research

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: OKA, MELVIN, SUSUMU

Inventor name: MURNANE, AMY, ANNE

Inventor name: RAMOS, LUCIANO

RHK1 Main classification (correction)

Ipc: C12N 5/06

A4 Supplementary search report drawn up and despatched

Effective date: 19931018

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19951106

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19981218

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1012417

Country of ref document: HK